A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: Neurokinin-1 receptor dependent mechanisms may regulate urinary frequency and urgency. We conducted this study to assess the efficacy and tolerability of the neurokinin-1 receptor antagonist serlopitant vs placebo or tolterodine in patients with overactive bladder. MATERIALS AND METHODS: This randomized, double-blind, 69-center trial enrolled adults with overactive bladder (8 or more average daily micturitions and 1 or more daily urge incontinence episodes). After a 1-week placebo run-in the patients were randomized to 8 weeks of daily 0.25, 1 or 4 mg serlopitant, 4 mg tolterodine extended release or placebo. Patients kept 7-day voiding diaries. The primary end point was change from baseline in micturitions per day. Secondary end points included urgency, total incontinence, urge incontinence episodes and incidence of dry mouth. RESULTS: Of 557 patients randomized 476 completed the trial and had valid efficacy data for analysis. Mean change from baseline in daily micturitions was significantly greater for 0.25 (-1.1) and 4 mg (-1.1) serlopitant, and for tolterodine (-1.5) than for placebo (-0.5), but not for 1 mg serlopitant (-0.8). No serlopitant dose response was demonstrated. Tolterodine was numerically superior to all doses of serlopitant in mean micturitions per day and secondary end points. The incidence of dry mouth on serlopitant (3.3%) was comparable to placebo (4.6%) and lower than tolterodine (8.8%). Serlopitant was generally well tolerated. CONCLUSIONS: Serlopitant (0.25 and 4 mg) significantly decreased the primary end point of daily micturitions but not the secondary end points compared with placebo. Serlopitant was generally well tolerated. Thus, NK-1 receptor antagonists may have a role in the treatment of overactive bladder but this compound does not offer advantages in efficacy compared to tolterodine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IRWIN, D. E., MILSOM, I., KOPP, Z., ABRAMS, P., & CARDOZO, L. (2006) · BJU International · doi:10.1111/j.1464-410x.2005.05889.x · Cited by 319 · cited 1×
“© 2010 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RES such as difficulty performing activities of daily living, depression and stress.(4) Epidemiological surveys reveal that approximately 17% of adults older than 40 years have OAB.”
Method
Cited by
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline
Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., Das, A. K., Foster, H. E., Scarpero, H. M., Tessier, C. D., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.09.079 · Cited by 710
Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C., & Bunnett, N. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00031.2013 · Cited by 628
“A large trial of patients with overactive bladder revealed that although the NK1R antagonist serlopitant decreased the daily number of urination episodes compared with placebo, it was no more effective than tolterodine (M2/M3 muscarinic receptor antagonist) and, unlike tolterodine, serlopitant did not reduce urgency o…”
Buser, N., Ivic, S., Kessler, T. M., Kessels, A. G. H., & Bachmann, L. M. (2012) · European Urology · doi:10.1016/j.eururo.2012.08.060 · Cited by 167
“Our searches identified 21 additional papers since publications of the previous study [21,22,32,34,40,41, 45,47,50,54,55,63,64,67,71,74,78,88,93,97,98].”
BackgroundStänder, S., Kwon, P., Hirman, J., Perlman, A. J., Weisshaar, E., Metz, M., & Luger, T. A. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.052 · Cited by 118
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus
Ständer, S., Spellman, M. C., Kwon, P., & Yosipovitch, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1638910 · Cited by 26
Metadata
- Authors
- Frenkl, T. L., Zhu, H., Reiss, T., Seltzer, O., Rosenberg, E., & Green, S.
- Venue
- Journal of Urology
- Published
- 2010-08
- Volume
- 184
- Issue
- 2
- Pages
- 616-622
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W1964287543
- Cited by
- 65
- References
- 1
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.